These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
586 related articles for article (PubMed ID: 36051467)
1. Accuracy and Limitations of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients with Positive Nodes. Aragon-Sanchez S; Oliver-Perez MR; Madariaga A; Tabuenca MJ; Martinez M; Galindo A; Arroyo ML; Gallego M; Blanco M; Ciruelos-Gil EM Breast J; 2022; 2022():1507881. PubMed ID: 36051467 [TBL] [Abstract][Full Text] [Related]
2. Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer. Simons JM; van Nijnatten TJA; van der Pol CC; van Diest PJ; Jager A; van Klaveren D; Kam BLR; Lobbes MBI; de Boer M; Verhoef C; Sars PRA; Heijmans HJ; van Haaren ERM; Vles WJ; Contant CME; Menke-Pluijmers MBE; Smit LHM; Kelder W; Boskamp M; Koppert LB; Luiten EJT; Smidt ML JAMA Surg; 2022 Nov; 157(11):991-999. PubMed ID: 36069889 [TBL] [Abstract][Full Text] [Related]
3. Axillary ultrasound after neoadjuvant therapy reduces the false-negative rate of sentinel lymph node biopsy in patients with cytologically node-positive breast cancer. Liu Y; Wang Y; Feng S; Xu Z; Yao M; Huang X; Li P; Wu L; Liu C; Chen X; Liang C; Liu Z Breast Cancer Res Treat; 2023 Feb; 197(3):515-523. PubMed ID: 36513955 [TBL] [Abstract][Full Text] [Related]
4. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. Boughey JC; Suman VJ; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Kuerer HM; Bowling M; Flippo-Morton TS; Byrd DR; Ollila DW; Julian TB; McLaughlin SA; McCall L; Symmans WF; Le-Petross HT; Haffty BG; Buchholz TA; Nelson H; Hunt KK; JAMA; 2013 Oct; 310(14):1455-61. PubMed ID: 24101169 [TBL] [Abstract][Full Text] [Related]
5. The Impact of Neoadjuvant Chemotherapy on Axillary Surgical Management of Patients With Breast Cancer and Positive Axillary Lymph Nodes. Cipolla C; Lupo S; Grassi N; Battaglia MC; Mesi C; Scandurra G; Gebbia V; Valerio MR Anticancer Res; 2024 May; 44(5):2047-2053. PubMed ID: 38677748 [TBL] [Abstract][Full Text] [Related]
6. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. Caudle AS; Yang WT; Krishnamurthy S; Mittendorf EA; Black DM; Gilcrease MZ; Bedrosian I; Hobbs BP; DeSnyder SM; Hwang RF; Adrada BE; Shaitelman SF; Chavez-MacGregor M; Smith BD; Candelaria RP; Babiera GV; Dogan BE; Santiago L; Hunt KK; Kuerer HM J Clin Oncol; 2016 Apr; 34(10):1072-8. PubMed ID: 26811528 [TBL] [Abstract][Full Text] [Related]
7. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Classe JM; Loaec C; Gimbergues P; Alran S; de Lara CT; Dupre PF; Rouzier R; Faure C; Paillocher N; Chauvet MP; Houvenaeghel G; Gutowski M; De Blay P; Verhaeghe JL; Barranger E; Lefebvre C; Ngo C; Ferron G; Palpacuer C; Campion L Breast Cancer Res Treat; 2019 Jan; 173(2):343-352. PubMed ID: 30343457 [TBL] [Abstract][Full Text] [Related]
8. Feasibility of targeted axillary dissection for de-escalation of surgical treatment after neoadjuvant chemotherapy in breast cancer. Aragón-Sánchez S; Ciruelos-Gil E; López-Marín L; Galindo A; Tabuenca-Mateos MJ; Jiménez-Arranz S; Colmenero-Hernández M; Oliver-Pérez MR Surg Oncol; 2022 Sep; 44():101823. PubMed ID: 36041377 [TBL] [Abstract][Full Text] [Related]
9. Targeted axillary dissection reduces residual nodal disease in clinically node- positive breast cancer after neoadjuvant chemotherapy. Cabıoğlu N; Karanlık H; Yılmaz R; Emiroğlu S; Tükenmez M; Bademler S; Şimşek DH; Kantarcı TR; Yirgin İK; Bayram A; Dursun M World J Surg Oncol; 2024 Jul; 22(1):178. PubMed ID: 38971793 [TBL] [Abstract][Full Text] [Related]
10. Improved false-negative rates using a novel patient selection flowchart in initially biopsy-proven node-positive breast cancer undergoing blue-dye alone guided sentinel lymph node biopsy after neoadjuvant chemotherapy. Chen M; Li S; Huang M; Guo J; Huang X; Guo W; Chen L; Lin Y; Jacobs L; Wang C; Fu F Breast Cancer Res Treat; 2022 Nov; 196(2):267-277. PubMed ID: 36100784 [TBL] [Abstract][Full Text] [Related]
11. Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Laws A; Hughes ME; Hu J; Barry WT; Dominici L; Nakhlis F; Barbie T; Duggan M; Weiss A; Rhei E; Carter K; Nimbkar S; Schnitt SJ; King TA Ann Surg Oncol; 2019 Nov; 26(12):3846-3855. PubMed ID: 31222687 [TBL] [Abstract][Full Text] [Related]
12. Sentinel lymph node biopsy after neoadjuvant chemotherapy predicts pathological axillary lymph node status in breast cancer patients with clinically positive axillary lymph nodes at presentation. Takei H; Yoshida T; Kurosumi M; Inoue K; Matsumoto H; Hayashi Y; Higuchi T; Uchida S; Ninomiya J; Kubo K; Oba H; Nagai S; Tabei T Int J Clin Oncol; 2013 Jun; 18(3):547-53. PubMed ID: 22588780 [TBL] [Abstract][Full Text] [Related]
13. A prospective feasibility study of sentinel node biopsy by modified Indigocarmine blue dye methods after neoadjuvant chemotherapy for breast cancer. Kida K; Ishikawa T; Yamada A; Shimizu D; Tanabe M; Sasaki T; Ichikawa Y; Endo I Eur J Surg Oncol; 2015 Apr; 41(4):566-70. PubMed ID: 25650249 [TBL] [Abstract][Full Text] [Related]
14. Sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy. Reitsamer R; Peintinger F; Rettenbacher L; Prokop E J Surg Oncol; 2003 Oct; 84(2):63-7. PubMed ID: 14502778 [TBL] [Abstract][Full Text] [Related]
15. Prediction of the number of positive axillary lymph nodes according to sentinel lymph node involvement and biological subtypes in patients receiving neoadjuvant chemotherapy. Yilmaz L; Kus T; Aytekin A; Aktas G; Uzun E; Maralcan G BMC Surg; 2024 Jul; 24(1):213. PubMed ID: 39030524 [TBL] [Abstract][Full Text] [Related]
16. Prospective study found that peripheral lymph node sampling reduced the false-negative rate of sentinel lymph node biopsy for breast cancer. Han C; Yang B; Zuo WS; Liu YS; Zheng G; Yang L; Zheng MZ Chin J Cancer; 2016 Apr; 35():35. PubMed ID: 27044285 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of Axillary Lymph Node Marking with Magseed® before and after Neoadjuvant Systemic Therapy in Breast Cancer Patients: MAGNET Study. Martínez M; Jiménez S; Guzmán F; Fernández M; Arizaga E; Sanz C Breast J; 2022; 2022():6111907. PubMed ID: 35855102 [TBL] [Abstract][Full Text] [Related]
18. Outcomes of Sentinel Node Biopsy for Women with Breast Cancer After Neoadjuvant Therapy: Systematic Review and Meta-Analysis of Real-World Data. Lin SQ; Vo NP; Yen YC; Tam KW Ann Surg Oncol; 2022 May; 29(5):3038-3049. PubMed ID: 35018590 [TBL] [Abstract][Full Text] [Related]
19. Clipping a Positive Lymph Node Improves Accuracy of Nodal Staging After Neoadjuvant Chemotherapy for Breast Cancer Patients, but Does It Drive Management Changes? Costarelli L; Arienzo F; Broglia L; La Pinta M; Scavina P; Meli EZ; Colavito MH; Ascarelli A; Campagna D; Mastropietro T; Manna E; Amato M; Andrulli AD; Schiavone A; Minelli M; Fortunato L Ann Surg Oncol; 2024 May; 31(5):3186-3193. PubMed ID: 38427160 [TBL] [Abstract][Full Text] [Related]
20. Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy-A Rare Event. Barrio AV; Montagna G; Mamtani A; Sevilimedu V; Edelweiss M; Capko D; Cody HS; El-Tamer M; Gemignani ML; Heerdt A; Kirstein L; Moo TA; Pilewskie M; Plitas G; Sacchini V; Sclafani L; Tadros A; Van Zee KJ; Morrow M JAMA Oncol; 2021 Dec; 7(12):1851-1855. PubMed ID: 34617979 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]